Cover Image
Market Research Report

Global Pain Management Drugs Market Forecast 2019-2027

Published by Inkwood Research Product code 754276
Published Content info 134 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Pain Management Drugs Market Forecast 2019-2027
Published: December 10, 2018 Content info: 134 Pages
Description

KEY FINDINGS

Pain is a distressing sensory and emotional feeling that occurs due to tissue damage or illness that can take place for short-term (acute pain) to long-term (chronic pain). Pain management drugs market supplies medications and therapies which upon employs an interdisciplinary approach for easing the suffering and improving the quality of life of such victims or patients. The global market for pain management drugs is escalating at 3.88% CAGR during the forecast period of 2019-2027. The market has been valued $ XX millions in its base year of 2018 and is expected to reach an astounding sum of $ XX millions by the end of the forecast period, essentially, 2027.

MARKET INSIGHTS

The factors that are the sole drivers for the growth of the pain management drugs market are the public demand for medications with fewer side-effects and their consequential availability, and the rise in global geriatric population that could increase the use of pain medications are expected to drive the global market for pain management drugs. Alongside these circumstances, with the advancement in technology, there are researchers who are trying to develop abuse-deterrent drugs due to the increase in the number of drug abuse cases globally. This can pave way for the entry of newer drugs for the said market. Patent expiration of pain relieving drugs can decrease their market value, leading to the decrease in revenue earned for the global market. This can potentially affect the market growth.

REGIONAL INSIGHTS

The global pain management drugs market has been segmented on the basis of several region regions, which are the North America, Europe, Asia-Pacific and the collective countries from the Rest of the World. North America holds the largest share by revenue $ XX millions in the year 2018. This is attributable to the fact that this region has a large number of aging inhabitants and favorable regulatory conditions.

But conversely, Asia-Pacific region has the fastest growing market for pain management drugs.

Table of Contents
Product Code: 22716

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. OPIOIDS MARKET HOLDS THE LARGEST MARKET SHARE IN TERMS OF DRUG CLASS
    • 3.2.2. CANCER PAIN INDICATION IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. GROWTH IN THE INCIDENCE AND PREVALENCE OF CHRONIC DISEASES
    • 4.2.2. THE RISE IN AWARENESS REGARDING THE SIDE-EFFECTS OF PAIN MEDICATION
    • 4.2.3. RISE IN GERIATRIC POPULATION
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. ACCESSIBILITY OF ALTERNATIVE THERAPIES
    • 4.3.2. INCREASE IN DRUG MISTREATMENT
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. TECHNOLOGICAL ADVANCEMENT
    • 4.4.2. GROWTH POTENTIAL IN UNTAPPED ECONOMIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. PATENT EXPIRATION

5. MARKET BY DRUG CLASS

  • 5.1. NSAIDS
  • 5.2. ANESTHETICS
  • 5.3. ANTICONVULSANTS
  • 5.4. ANTI-MIGRAINE AGENTS
  • 5.5. ANTIDEPRESSANTS
  • 5.6. OPIOIDS
  • 5.7. NON-NARCOTIC ANALGESICS

6. MARKET BY INDICATION

  • 6.1. ARTHRITIC PAIN
  • 6.2. NEUROPATHIC PAIN
  • 6.3. CANCER PAIN
  • 6.4. CHRONIC BACK PAIN
  • 6.5. POST-OPERATIVE PAIN
  • 6.6. MIGRAINE
  • 6.7. FIBROMYALGIA

7. KEY ANALYTICS

  • 7.1. PORTER'S FIVE FORCE MODEL
    • 7.1.1. THREAT OF NEW ENTRANTS
    • 7.1.2. THREAT OF SUBSTITUTE
    • 7.1.3. BARGAINING POWER OF SUPPLIERS
    • 7.1.4. BARGAINING POWER OF BUYERS
    • 7.1.5. THREAT OF COMPETITIVE RIVALRY
  • 7.2. REGULATORY FRAMEWORK
  • 7.3. OPPORTUNITY MATRIX
  • 7.4. VALUE CHAIN ANALYSIS
  • 7.5. VENDOR LANDSCAPE

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. THE UNITED STATES
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. GERMANY
    • 8.2.2. FRANCE
    • 8.2.3. THE UNITED KINGDOM
    • 8.2.4. ITALY
    • 8.2.5. SPAIN
    • 8.2.6. REST OF EUROPE
  • 8.3. ASIA-PACIFIC
    • 8.3.1. JAPAN
    • 8.3.2. CHINA
    • 8.3.3. INDIA
    • 8.3.4. AUSTRALIA
    • 8.3.5. SOUTH KOREA
    • 8.3.6. REST OF ASIA-PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. LATIN AMERICA
    • 8.4.2. MIDDLE EAST AND AFRICA

9. COMPETITIVE LANDSCAPE

  • 9.1. MARKET SHARE ANALYSIS
  • 9.2. COMPANY PROFILES
    • 9.2.1. ABBOTT LABORATORIES
      • 9.2.1.1. COMPANY OVERVIEW
      • 9.2.1.2. PRODUCT PORTFOLIO
      • 9.2.1.3. SCOT ANALYSIS
      • 9.2.1.4. STRATEGIC INITIATIVES
    • 9.2.2. ACURA PHARMACEUTICALS, INC.
      • 9.2.2.1. COMPANY OVERVIEW
      • 9.2.2.2. PRODUCT PORTFOLIO
      • 9.2.2.3. STRATEGIC INITIATIVES
    • 9.2.3. CIPHER PHARMACEUTICALS INC.
      • 9.2.3.1. COMPANY PROFILES
      • 9.2.3.2. PRODUCT PORTFOLIO
      • 9.2.3.3. STRATEGIC INITIATIVES
    • 9.2.4. DAIICHI SANKYO, INC.
      • 9.2.4.1. COMPANY OVERVIEW
      • 9.2.4.2. PRODUCT PORTFOLIO
      • 9.2.4.3. STRATEGIC INITIATIVES
    • 9.2.5. EGALET CORP.
      • 9.2.5.1. COMPANY OVERVIEW
      • 9.2.5.2. PRODUCT PORTFOLIO
      • 9.2.5.3. STRATEGIC INITIATIVES
    • 9.2.6. ELI LILLY AND COMPANY
      • 9.2.6.1. COMPANY OVERVIEW
      • 9.2.6.2. PRODUCT PORTFOLIO
      • 9.2.6.3. SCOT ANALYSIS
      • 9.2.6.4. STRATEGIC INITIATIVES
    • 9.2.7. GLAXOSMITHKLINE
      • 9.2.7.1. COMPANY OVERVIEW
      • 9.2.7.2. PRODUCT PORTFOLIO
      • 9.2.7.3. SCOT ANALYSIS
      • 9.2.7.4. STRATEGIC INITIATIVES
    • 9.2.8. HIKMA PHARMACEUTICALS PLC
      • 9.2.8.1. COMPANY OVERVIEW
      • 9.2.8.2. PRODUCT PORTFOLIO
      • 9.2.8.3. STRATEGIC INITIATIVES
    • 9.2.9. JOHNSON & JOHNSON
      • 9.2.9.1. COMPANY OVERVIEW
      • 9.2.9.2. PRODUCT PORTFOLIO
      • 9.2.9.3. SCOT ANALYSIS
      • 9.2.9.4. STRATEGIC INITIATIVES
    • 9.2.10. LUPIN LTD.
      • 9.2.10.1. COMPANY OVERVIEW
      • 9.2.10.2. PRODUCT PORTFOLIO
      • 9.2.10.3. STRATEGIC INITIATIVES
    • 9.2.11. PFIZER, INC.
      • 9.2.11.1. COMPANY PROFILES
      • 9.2.11.2. PRODUCT PORTFOLIO
      • 9.2.11.3. SCOT ANALYSIS
      • 9.2.11.4. STRATEGIC INITIATIVES
    • 9.2.12. PURDUE PHARMA L.P.
      • 9.2.12.1. COMPANY OVERVIEW
      • 9.2.12.2. PRODUCT PORTFOLIO
      • 9.2.12.3. STRATEGIC INITIATIVES
    • 9.2.13. MERCK & CO., INC.
      • 9.2.13.1. COMPANY PROFILES
      • 9.2.13.2. PRODUCT PORTFOLIO
      • 9.2.13.3. SCOT ANALYSIS
      • 9.2.13.4. STRATEGIC INITIATIVES
    • 9.2.14. NOVARTIS
      • 9.2.14.1. COMPANY OVERVIEW
      • 9.2.14.2. PRODUCT PORTFOLIO
      • 9.2.14.3. SCOT ANALYSIS
      • 9.2.14.4. STRATEGIC INITIATIVES
    • 9.2.15. INSYS THERAPEUTICS, INC.
      • 9.2.15.1. COMPANY OVERVIEW
      • 9.2.15.2. PRODUCT PORTFOLIO
      • 9.2.15.3. STRATEGIC INITIATIVES

LIST OF TABLES

  • TABLE 1 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 2 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 3 GLOBAL NSAIDS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 4 GLOBAL ANESTHETICS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL ANTICONVULSANTS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL ANTI-MIGRAINE AGENTS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 7 GLOBAL ANTIDEPRESSANTS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 8 GLOBAL OPIOIDS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 9 GLOBAL NON-NARCOTIC ANALGESICS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL ARTHRITIC PAIN MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 12 GLOBAL NEUROPATHIC PAIN MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL CANCER PAIN MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 14 GLOBAL CHRONIC BACK PAIN MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 15 GLOBAL POST-OPERATIVE PAIN MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL MIGRAINE MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 17 GLOBAL FIBROMYALGIA MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 18 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 19 NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 20 THE UNITED STATES PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 21 THE UNITED STATES PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 22 CANADA PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 23 CANADA PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 24 EUROPE PAIN MANAGEMENT DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 25 GERMANY PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 26 GERMANY PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 27 FRANCE PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 28 FRANCE PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 29 THE UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 30 THE UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 31 ITALY PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 32 ITALY PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 33 SPAIN PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 34 SPAIN PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 35 ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 36 JAPAN PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 37 JAPAN PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 38 CHINA PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 39 CHINA PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 40 INDIA PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 41 INDIA PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 42 AUSTRALIA PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 43 AUSTRALIA PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 44 SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
  • TABLE 45 SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)
  • TABLE 46 REST OF WORLD PAIN MANAGEMENT DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 GLOBAL PAIN MANAGEMENT DRUGS MARKET SHARE BY DRUG CLASS 2018 & 2027 (%)
  • FIGURE 3 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY NSAIDS 2019-2027 ($ MILLION)
  • FIGURE 4 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY ANESTHETICS 2019-2027 ($ MILLION)
  • FIGURE 5 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY ANTICONVULSANTS 2019-2027 ($ MILLION)
  • FIGURE 6 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY ANTI-MIGRAINE AGENTS 2019-2027 ($ MILLION)
  • FIGURE 7 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY ANTIDEPRESSANTS 2019-2027 ($ MILLION)
  • FIGURE 8 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY OPIOIDS 2019-2027 ($ MILLION)
  • FIGURE 9 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY NON-NARCOTIC ANALGESICS 2019-2027 ($ MILLION)
  • FIGURE 10 GLOBAL PAIN MANAGEMENT DRUGS MARKET SHARE BY INDICATION 2018 & 2027 (%)
  • FIGURE 11 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY ARTHRITIC PAIN 2019-2027 ($ MILLION)
  • FIGURE 12 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY NEUROPATHIC PAIN 2019-2027 ($ MILLION)
  • FIGURE 13 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY CANCER PAIN 2019-2027 ($ MILLION)
  • FIGURE 14 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY CHRONIC BACK PAIN 2019-2027 ($ MILLION)
  • FIGURE 15 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY POST-OPERATIVE PAIN 2019-2027 ($ MILLION)
  • FIGURE 16 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY MIGRAINE 2019-2027 ($ MILLION)
  • FIGURE 17 GLOBAL PAIN MANAGEMENT DRUGS MARKET BY FIBROMYALGIA 2019-2027 ($ MILLION)
  • FIGURE 18 PORTER'S FIVE FORCE MODEL
  • FIGURE 19 GLOBAL PAIN MANAGEMENT DRUGS MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 20 THE UNITED STATES PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 21 CANADA PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 22 GERMANY PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 23 FRANCE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 24 THE UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 25 ITALY PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 26 SPAIN PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 27 REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 28 JAPAN PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 29 CHINA PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 30 INDIA PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 31 AUSTRALIA PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 32 SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 33 REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 34 LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 35 MIDDLE EAST AND AFRICA PAIN MANAGEMENT DRUGS MARKET 2019-2027 ($ MILLION)
  • FIGURE 36 PAIN MANAGEMENT MARKET SHARE ANALYSIS 2017 (%)
Back to Top